Your AI-Trained Oncology Knowledge Connection!
The first-line combination of durvalumab and chemotherapy, with or without tremelimumab, led to a statistically significant improvement in progression-free survival compared with chemotherapy alone in patients with metastatic non–small cell lung cancer, according to data from the phase 3 POSEIDON trial.
The safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone were confirmed for patients with newly diagnosed multiple myeloma with no immediate intent for transplant.
Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.
For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.
Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.
The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.
Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.
Iberdomide combined with dexamethasone and either daratumumab, bortezomib, or carfilzomib showed efficacy and tolerability in patients with relapsed or refractory multiple myeloma.
Updated data from a phase 2 trial presented at the 2021 World Conference on Lung Cancer showed that neoadjuvant osimertinib induced a pathologic complete response among patients with surgically resectable EGFR-mutant non–small cell lung cancer.
Mobocertinib demonstrated clinical activity in previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer whether or not they received a prior PD-1/PD-L1 inhibitor.
The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.
The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.
Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.
Selpercatinib demonstrated robust and durable efficacy with a favorable safety profile in Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.
Sotorasib elicited systemic durable anticancer activity with intracranial complete responses and continued intracranial stabilization in patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases previously treated with radiation or surgery.
Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.
Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.
The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.
In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.
In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.
Mobocertinib improved patient-reported outcomes in those with previously treated non–small cell lung cancer whose tumors harbored EGFR exon 20 insertion mutations.
ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.
Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.
Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.
David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).
The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.
Biomarkers of response to immunotherapy, characterized by high interferon signaling and expression of MHC-II related genes, predicted for improved survival in patients with advanced hepatocellular carcinoma following immediate treatment with a PD-1 inhibitor but not in those who had first received treatment with a TKI.
Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.
Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.
Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.
